Altimmune, Inc. (NASDAQ:ALT) Q3 2019 Earnings Conference Call November 14, 2019 8:30 AM ET Company Participants Monique Kosse – Investor Relations-LifeSci Advisors Vipin Garg – Chief Executive Officer Scott Harris – Chief Medical Officer Will Brown – Chief Financial Officer Conference Call Participants Suowei Wu – B. Riley FBR Operator Thank you for standing by. This is the conference operator. Welcome to the Altimmune, Inc. Third Quarter 2019 Earnings Conference Call. As a reminder, all participants are in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Altimmune, Inc. (NASDAQ:ALT) Q2 2019 Earnings Conference Call August 14, 2019 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Vipin Garg - President & CEO Scot Roberts - Chief Scientific Officer Will Brown - CFO John Nestor - Founder, Spirfire Pharma, Inc. Conference Call Participants Jim Molloy - Alliance Global Group Jay Olson - Oppenheimer Operator Greetings and welcome to the Altimmune, Inc. second-quarter 2019 earnings conference call. [Operator Instructions]. Please note this conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Altimmune, Inc. (NASDAQ:ALT) Q1 2019 Earnings Conference Call May 15, 2019 8:30 AM ET Company Participants Vipin Garg - Chief Executive Officer Will Brown - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Jerry Isaacson - ROTH Capital Operator Greetings, and welcome to the Altimmune First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2726770 State or Other Jurisdiction of ...

Altimmune, Inc. (NASDAQ:ALT) Q4 2018 Earnings Conference Call April 2, 2019 8:30 AM ET Company Participants Paul Arndt - LifeSci Advisors Vipin Garg - Chief Executive Officer Will Brown - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Jerry Isaacson - ROTH Capital Partners Operator Greetings and welcome to the Altimmune, Inc. Fourth Quarter and Fiscal Year 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 ☐ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-32587 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 20-2726770 (State or other jurisdiction of incorporatio ...